Skip to main content
. 2020 May 28;12(6):1394. doi: 10.3390/cancers12061394

Table 1.

Characteristics and main results of studies exploring the use of 11C-Choline or 18F-Choline in multiple myeloma.

References Number of Patients Study Design Time of Imaging Index Test Choline Administered Activity Choline PET Scanning Time Post-Injection Reference Test Number of Bone FL on Choline PET/CT (Matched/
Unmatched)
Number of Bone FL on FDG- or MTH PET/CT (Matched/
Unmatched)
Number of EMD foci on Choline PET/CT (Matched/
Unmatched)
Number of EMD foci on FDG- or MTH PET/CT (Matched/
Unmatched)
Mean or Median (range) SUVmax of Choline PET Mean or Median (range) SUVmax of FDG- or MTH PET
Nanni et al. (2007) [25] 10 Retrospective Relapse or f/up post treatment 11C-Choline
18F-FDG
5.3 MBq/kg 5 min. None 37 (21/16) 22 (21/1) 3 (2/1) 1 (1/0) 5.0 (NS) 3.8 (NS)
Cassou-Mounat et al. (2016) [26] 21 Retrospective Relapse or Progression 18F-Choline
18F-FDG
3 MBq/kg 10–20 min. None 121 (65/56) 69 (65/4) 3 (3/3) 3 (3/3) 3.8-5.7 (1.6–16) 3-4.5 (1.6–20.6)
Lapa et al. (2019) [27] 19 Retrospective Progression or f/up post-treatment 11C-Choline
11C-MTH
719 ± 86 MBq 5 min. None 91* (91/0)
>50: 4 patients
112 ** (87/25)
>50: 7 patients
0 0 5.7 (3.5–14.6) 9.3 (3.5–30.9)

MTH: Methionine; FL: Focal bone Lesion; EMD: Extra-Medullary-Disease; NS: Not Specified *91 FL were found in 15 patients. The remaining four patients had innumerable FL (>50) which were all matched by MTH PET/CT. ** 112 FL were found in 12 patients. The remaining 7 patients had innumerable FL (>50) with 3 of them having less than 3 lesions on Choline PET/CT.